The Globe and Mail reports in its Wednesday, April 24, edition that RBC Capital analyst Douglas Miehm is sticking with his "sector perform" recommendation for Bausch Health. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm cut his share target to $11 from $12 (all figures U.S.). Analysts on average target the shares at $10.17. Mr. Miehm says in a note: "Bausch Health will report Q1/24 results on May 2, one day after Bausch + Lomb's Q1 results. We estimate Q1/24 revenue of $2.13-billion (vs. FactSet cons. $2.15-billion) and adj. EBITDA of $682-million (vs. FactSet cons. $730-million). We expect the focus to be on a potential Bausch + Lomb distribution to Bausch Health shareholders and the factors influencing such a decision. We believe that following the appellate court's ruling, Bausch Health stands in a stronger position to move forward with a potential Baucsh + Lomb distribution. However, Amneal's ANDA submission has likely added additional complexity to the situation." The Globe reported on Sept. 2, 2022, and April 5, 2024, that Mr. Miehm continued to rate the Baucsh Health "sector perform." It was then worth $8.67 and $14.15.